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The variability in the response to antipsychotic medication 
in schizophrenia may reflect between-patient differences in 
neurobiology. Recent cross-sectional neuroimaging studies 
suggest that a poorer therapeutic response is associated 
with relatively normal striatal dopamine synthesis capacity 
but elevated anterior cingulate cortex (ACC) glutamate 
levels. We sought to test whether these measures can dif-
ferentiate patients with psychosis who are antipsychotic 
responsive from those who are antipsychotic nonresponsive 
in a multicenter cross-sectional study. 1H-magnetic reso-
nance spectroscopy (1H-MRS) was used to measure gluta-
mate levels (Glucorr) in the ACC and in the right striatum 
in 92 patients across 4 sites (48 responders [R] and 44 
nonresponders [NR]). In 54 patients at 2 sites (25 R and 29 
NR), we additionally acquired 3,4-dihydroxy-6-[18F]fluoro-
l-phenylalanine (18F-DOPA) positron emission tomography 
(PET) to index striatal dopamine function (Ki
cer, min−1). The 
mean ACC Glucorr was higher in the NR than the R group 
after adjustment for age and sex (F1,80 = 4.27; P = .04). This 
was associated with an area under the curve for the group 
discrimination of 0.59. There were no group differences in 
striatal dopamine function or striatal Glucorr. The results 
provide partial further support for a role of ACC glutamate, 
but not striatal dopamine synthesis, in determining the na-
ture of the response to antipsychotic medication. The low 
discriminative accuracy might be improved in groups with 
greater clinical separation or increased in future studies that 
focus on the antipsychotic response at an earlier stage of 
the disorder and integrate other candidate predictive bio-
markers. Greater harmonization of multicenter PET and 
1H-MRS may also improve sensitivity.
Key words:  1H-MRS/PET/antipsychotic response, 
treatment resistance/schizophrenia
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Introduction 
The degree to which symptoms of schizophrenia will im-
prove with antipsychotic medication is extremely variable. 
For some patients, antipsychotics can be very effective in 
improving symptoms. However, a majority of patients 
experience only a partial improvement,1–3 and around a 
third of all patients meet criteria for treatment-resistant 
schizophrenia (TRS), for which the only recommended 
antipsychotic is clozapine.4–6 The difficulty of identifying 
TRS by clinical criteria, combined with a reluctance to 
prescribe clozapine, leads to a delay in clozapine initia-
tion during which time patients are exposed to ineffec-
tive medications and symptoms are active and disabling.7 
There is an initial indication that delay in clozapine pre-
scription is associated with a worse response when cloza-
pine is eventually prescribed.8
Emerging biological and epidemiological evidence sug-
gests that antipsychotic nonresponsive illness could be 
categorically distinct from antipsychotic responsive ill-
ness.9–14 Elucidating the pathophysiology of antipsychotic 
nonresponse could identify new targets for drug develop-
ment and could also enable the development of predictive 
biomarkers to identify such patients early in the illness, 
allowing treatment with clozapine to begin earlier.
A prominent neurochemical hypothesis of schizophrenia 
centers on elevated dopamine synthesis and release in the 
striatum, arising from increased activity in mesostriatal do-
pamine neurons.15 The blockade of striatal D2 dopamine 
receptors is considered a critical feature of antipsychotic 
efficacy.16 While the response may require a threshold level 
of D2 occupancy, in antipsychotic nonresponsive schizo-
phrenia, symptoms may persist despite high levels of D2 
blockade.17,18 This raises the possibility that antipsychotic 
nonresponsive patients have a different pathophysiology 
that is not addressed by D2 blockade.
19 Recently, molecular 
imaging studies have shown that striatal dopamine syn-
thesis capacity is lower in TRS relative to that in patients 
who respond to antipsychotics.20,21 In longitudinal studies, 
higher levels of striatal D2 occupancy by dopamine
22,23 
and striatal dopamine synthesis capacity24 are associated 
with a greater response to antipsychotic treatment. Thus, 
biomarkers of striatal hyperdopaminergia may be predic-
tive of an increased likelihood to respond to first-line (D2 
blocking) antipsychotic treatment.
If  TRS is not associated with abnormal striatal dopa-
mine synthesis capacity, then the pathophysiology prob-
ably lies elsewhere. One possibility is that TRS arises 
due to abnormal glutamatergic signaling, particularly in 
cortical areas.25 A  series of cross-sectional studies have 
indicated that poor antipsychotic response is associated 
with a higher level of glutamate metabolites in the an-
terior cingulate cortex (ACC)14,26–28 relative to levels in 
patients who have shown a good response or healthy 
volunteers. In first-episode psychosis, a higher level 
of ACC glutamate is predictive of a worse response to 
antipsychotic treatment.29 Higher frontal glutamate me-
tabolites are also predictive of a poor response following 
reinitiation of antipsychotic treatment.30 In the striatum, 
glutamate metabolites may be elevated at illness onset31,32 
but the relationship with the antipsychotic response is 
less clear.27,28,33–35 These observations may be particularly 
important in the context of the substantial efforts to de-
velop glutamatergic drugs for schizophrenia, as they may 
suggest that glutamate modulation may be more effective 
in TRS than in antipsychotic-responsive patients.
So far, cross-sectional studies of dopaminergic20–23 or glu
tamatergic14,26–28,33,36 function in relation to antipsychotic 
response have been single-center studies that have recruited 
relatively small and homogenous patient cohorts. A  key 
step in scaling this research toward developing predictive 
biomarkers for future stratified clinical trials is to test for 
these associations in a larger, more clinically representa-
tive patient sample and to determine the accuracy of group 
discrimination. The main aim of the current study was, 
therefore, to determine if glutamate levels in the ACC and 
striatum and striatal dopamine synthesis capacity differ-
entiate antipsychotic nonresponsive from antipsychotic re-
sponsive psychosis in a multicenter cross-sectional sample. 
We hypothesized that, compared with the antipsychotic-
responsive group, antipsychotic nonresponse would be 
characterized by lower striatal dopamine synthesis ca-
pacity and higher glutamate levels in the striatum and 
ACC. A secondary aim was to investigate relationships be-
tween ACC and striatal glutamate and striatal dopamine 
synthesis capacity in the same individuals.
Methods
Regulatory Approvals
The study had NHS Research Ethics Committee (15/
LO/0038) and Administration of Radioactive Substances 
Advisory Committee (630/3764/32558) approvals. 
Participation required the provision of written informed 
consent.
Participants
Study participants were recruited and assessed across 4 
UK sites: King’s College London (KCL), University of 
Manchester (UoM), University of Edinburgh (UoE), 
and Cardiff  University (CU). Inclusion criteria required 
that participants were aged between 18 and 65, met 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) criteria for schizophrenia or schizophreniform 
disorder, and were able to understand and consent to the 
study procedures. Exclusion criteria included currently 
meeting International Classification of Diseases (ICD) 
criteria for harmful substance misuse, or psychotic dis-
order secondary to substance misuse, pregnancy, previous 
severe head injury involving loss of consciousness for >5 
minutes, and for  Magnetic Resonance Imaging (MRI) 
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presence of any contraindications to MRI at 3 tesla in-
cluding implanted electronic devices or metallic objects. 
Treatment with clozapine in the last 3 months was an ex-
clusion criterion, as the superior efficacy of clozapine in 
TRS37 could reflect differential biological effects. The co-
hort reflect a new patient sample, separate to those in our 
previous reports.14,26,29,36,38 Volunteers were reimbursed for 
participating in MRI and positron emission tomography 
(PET) scans.
The  Mini International Neuropsychiatric Interview 
(MINI)39 was used to aid clinical diagnosis. Medication 
history and antipsychotic response were recorded 
through a structured interview and review of medical 
records. Antipsychotic doses were converted to chlor-
promazine equivalent (CPZE) doses using the method of 
Davis and Chen,40 with the exception of amisulpride that 
used defined daily dose (https://www.whocc.no/atc_ddd_
index/). Illness severity was evaluated using the Positive 
and Negative Syndrome Scale (PANSS)41 and the Clinical 
Global Impression scale for Schizophrenia (CGI-SCH).42
Definition of Antipsychotic Responder and 
Antipsychotic Nonresponder groups
Antipsychotic Responders (R) were defined as having had 
(1) treatment with only 1 antipsychotic drug since illness 
onset, or, if  there were any treatment changes, then these 
were due to adverse effects as opposed to nonresponse; 
(2) a CGI-SCH severity score of <4; (3) a PANSS total 
score of <6043; and (4) a compliance rating scale (CRS) 
score44 of >3.
Antipsychotic nonresponders (NR) were defined as 
having (1) documented treatment with at least 2 anti-
psychotics for >4 weeks each, at doses above the min-
imum therapeutic doses as defined by the British National 
Formulary; (2) a CGI-SCH severity score of >3; (3) a 
PANSS total score of at least 70; and (4) a CRS of >3. 
The targets for participant enrollment differed by site, but 
each site aimed to recruit a 1:1 ratio of R and NR.
Proton Magnetic Resonance Spectroscopy 
(1H-Magnetic Resonance Spectroscopy)
Glutamate levels were measured using 1H-magnetic res-
onance spectroscopy (1H-MRS) at 3 tesla at all 4 sites 
(see supplementary Methods). Non-rotated 1H-MRS 
voxels were positioned in the ACC (20 × 20 × 20 mm3; 
supplementary figure 1)26 and in the right striatum (20 × 
20  × 20  mm3; supplementary figure  2).31 Spectra were 
acquired using Point RESolved Spectroscopy (PRESS, 
echo time = 35 ms; repetition time = 2000 ms; 128 aver-
ages, bandwidth/sample frequency ±2500 Hz, complex 
points  =  4096), and analyzed in LCModel version 6.3-
1L45 using a standard LCModel basis set. Representative 
spectra are provided in supplementary figure 3. Metabolite 
estimates were water-referenced. Gannet software (version 
2.0, http://www.gabamrs.com/) co-registered the 1H-MRS 
voxel to the corresponding T1-weighted image to deter-
mine the voxel tissue composition. Metabolite values were 
corrected for voxel tissue content using the formula:
Mcorr = M ∗ (WM+ 1.21 ∗ GM+ 1.55 ∗ CSF) / (WM+ GM)
where M is the uncorrected metabolite concentration, 
and WM, GM, and CSF indicate the percentages of 
tissue type in the voxel.46,47Further details are provided 
in the supplementary information. The primary outcome 
variable was Glucorr. For completeness, data for glutamate 
plus glutamine (Glxcorr), are also presented. 
Quality of 1H-MRS was determined by a review 
of LCModel estimates of spectral line width and sig-
nal-to-noise ratio. Spectra were excluded under any of the 
following criteria (1) absence of corresponding unsup-
pressed water acquisition; (2) compared with the overall 
mean for the voxel across all sites and participants, spec-
tral line width was 2 standard deviations above; or (3) 
spectral signal-to-noise ratio was 2 standard deviations 
below. Individual metabolite concentration estimates as-
sociated with Cramér Rao lower bounds (CRLB) > 20% 
were excluded. We relied on these quality control proced-
ures to identify and exclude any datasets potentially cor-
rupted by motion or other artifacts.
3,4-Dihydroxy-6-[18F]Fluoro-l-Phenylalanine Positron 
Emission Tomography
Striatal dopamine function was measured using 
3 ,4 -d ihydroxy-6 - [18F] f luoro-l -pheny la lan ine 
(18F-DOPA) PET. The study acquired 18F-DOPA PET 
scans in participants who had also participated in 1H-
MRS, at 2 sites (KCL and the UoM). To reduce the 
formation of radiolabeled 18F-DOPA metabolites,48 par-
ticipants received carbidopa (150  mg) and entacapone 
(400  mg) orally 1 hour before 18F-DOPA imaging.49 
Thirty seconds after the start of PET image acquisition, 
approximately 150 MBq of 18F-DOPA was administered 
by bolus intravenous injection. Emission data were ac-
quired in list mode over the 95-minute period immedi-
ately post-injection. 
Head movement was corrected for by frame-by-frame 
realignment using mutual information image registra-
tion.50,51 An 18F-DOPA template,52 together with a stri-
atal atlas,53 and cerebellum54 were nonlinearly normalized 
to each PET summation image in Statistical Parametric 
Mapping version 12 (http//www.fil.ion.ucl.ac.uk/spm) 
running in Matlab 2015b (Mathworks Inc.). This process 
allows automatic placement of volumes of interest (VOI) 
on individual PET images. The rate constant for the up-
take of 18F-DOPA in the striatum (Ki
cer min−1) was cal-
culated using graphical analysis adapted for a reference 
tissue input function, using the cerebellum as the refer-
ence region.55,56 We investigated Ki
cer across the whole 
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striatal VOI, and in associative, sensorimotor, and limbic 
functional subdivisions53 reflecting the topographical 
arrangement of corticostriatal projections.57 As previ-
ously,20,24 data are reported across both hemispheres and 
we did not predict laterality of effect. Supplementary 
figure  4 provides an example of 18F-DOPA PET Ki
cer 
images.
Statistical Analysis
Due to site effects (see supplementary information), 1H-
MRS metabolite concentration estimates and 18F-DOPA 
Ki
cer values were converted to Z-scores, calculated by 
subtracting the site mean from individual values, before 
dividing by the site standard deviation. Potential influ-
ences of age or sex58–61 on Glucorr or 
18F-DOPA Ki
cer min-1 
were determined by Pearson’s correlation coefficient and 
t-tests. For primary analyses, analysis of variance com-
pared Glucorr and 18F-DOPA Ki
cer min-1 in the antipsy-
chotic R and antipsychotic NR groups, using a threshold 
for statistical significance of P < .05 (uncorrected) in 
SPSS (version 23, IBM). Where the effects of age or sex 
were detected, these variables were added to the model. 
To evaluate the accuracy of ACC Glucorr and striatal 
18F-DOPA Ki
cer min-1 values in distinguishing between 
antipsychotic R and NR groups, receiver-operating 
curves (ROC) were estimated, using Stata (SE, version 
14). The secondary analysis investigated continuous rela-
tionships between Glucorr and 18F-DOPA Ki
cer min-1 and 
PANSS scores using Pearson’s correlation coefficient. 
Effects of Glucorr on 
18F-DOPA Ki
cer by the group were 
analyzed using analysis of variance.
Results
Participant Characteristics
Ninety-two participants (antipsychotic R, n  =  48; an-
tipsychotic NR, n  =  44) completed 1H-MRS imaging 
(table  1) and 54 (R, n  =  25; NR, n  =  29) completed 
18F-DOPA PET imaging (table 2). The demographic and 
clinical characteristics of the 1H-MRS and PET samples 
by the site are provided in supplementary tables 1 and 2. 
For participants who completed both 1H-MRS and PET, 
the mean interval between scans was 24.74 ± 25.06 days 
(range 1–116 days).
Glutamate Metabolite Levels
ACC Glucorr and Glxcorr were related to age (N = 86; Glucorr 
r = −.21; P = .05, Glxcorr r = −.27; P = .01; supplementary 
figure 4), and sex (mean ± s.d. Glucorr male: 0.10 ± 0.94; 
female: −0.52 ± 1.04; T84 = 2.21; P =  .03; Glxcorr male: 
0.11 ± 0.93; female: −0.56 ± 1.09; T84 = 2.40; P = .01). 
There were no significant effects of  current tobacco or 
cannabis use or antipsychotic CPZE dose (P > .14). The 
NR group had significantly higher ACC Glucorr levels 
compared with the R group after adjustment for age and 
sex (main effect of  group: Glucorr F1,81 = 4.99; P =  .03; 
η 2 = 0.06; table 3, figure 1). A similar result at threshold 
levels of  significance was detected for Glxcorr (F1,81 = 3.92; 
P = .05; η 2 = 0.05; table 3, figure 1). Interactions between 
group and age or group and sex did not show any evi-
dence of  an effect. After excluding participants who were 
currently taking benzodiazepines (n = 10) or antidepres-
sants (n = 14), the effects of  group on Glucorr remained 
borderline significant (P = .04 and P = .07, respectively). 
The effect of  group was not significant in unadjusted 
analysis (Glucorr F1,84 = 2.37; P = .13; Glxcorr F1,84 = 1.77; 
P  =  .19; table  3). ROC analysis of  non-adjusted ACC 
Glucorr levels in the R and NR groups returned an area 
under curve (AUC) of  0.59 (figure 2). Subsequent empir-
ical cut-point estimation returned an optimal cut point 
of  0.98, which was associated with a Youden index of 
0.22, sensitivity = 0.73, specificity = 0.49, and AUC of 
0.61. There were no significant correlations between 
ACC Glucorr and PANSS scores or CPZE dose (N = 86; 
r = −.04 to .15).
There was no association between striatal Glucorr or 
Glxcorr and age (N = 83; Glucorr r = −.13, P = .25; Glxcorr 
r  =  −.09, P  =  .44), or sex (Glucorr T81  =  0.30; P  =  .77; 
Glxcorr: T81 = 1.76; P = .08). There were also no significant 
effects of current tobacco or cannabis use or antipsy-
chotic CPZE dose (P > .07). There was no between-group 
difference in striatal Glucorr (F1,81 = 0.96; P = .33; figure 1) 
or Glxcorr (F1,81 = 1.39; P = .24; table 3), or significant cor-
relations between striatal Glucorr or Glxcorr and PANSS 
scores or CPZE dose (N = 83; r = −.17 to .11). Site differ-
ences were present across 1H-MRS data (supplementary 
tables 3 and 4; supplementary Results).
Striatal Dopamine Function
Striatal 18F-DOPA Ki
cer values were not associated with 
age (N = 54; r = .07; P = .61), sex (T52 = 0.66; P = .51), 
tobacco (F2,52 = .17; P = .85), cannabis use (F1,52 = 1.20; 
P = .28), or antipsychotic CPZE dose (r = .06; P = .67). 
Ki
cer did not differ between the R and NR groups 
(F1,52 = 1.24; P = .27; table 3, figure 1). ROC analysis of 
whole striatal 18F-DOPA Ki
cer in antipsychotic R and NR 
returned an AUC of 0.59. Ki
cer values were not associated 
with PANSS scores or CPZE dose (r = −.01 to .13).
Relationships Between Glutamate and Dopamine
There was no main effect of ACC Glucorr on striatal 
18F-DOPA Ki
cer (F1,50 = 1.03; P =  .31), but the interac-
tion between ACC Glucorr and group was significant 
(F1,50 = 6.53; P = .01). This was related to a positive re-
lationship between ACC Glucorr and striatal 18F-DOPA 
Ki
cer in NR (N = 29; r = .37; P = .05) but not in R (N = 25; 
r  =  −.31; P  =  .13). Striatal Glucorr was negatively asso-
ciated with striatal 18F-DOPA Ki
cer across the whole 
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sample (F1,50 = 4.97; P = .03), and there was no group by 
striatal Glucorr interaction (F1,50 = 2.02; P = .16).
Discussion
The main aim of this study was to test whether measures 
of  dopamine synthesis capacity in the striatum20,21 and 
glutamate concentration (Glucorr) in the ACC
14,26 could 
differentiate patients with antipsychotic-nonresponsive 
from antipsychotic-responsive schizophrenia. In line 
with our hypothesis, we found that ACC mean Glucorr was 
higher in the NR compared with the R group, which was 
significant when age and sex were included in the model. 
There were no between-group differences in striatal 
dopamine function nor in striatal Glucorr. These results 
are partially consistent with previous evidence that the 
degree of antipsychotic response in schizophrenia may 
be related to ACC glutamate concentration14,26–30 but 
not with evidence linking response to striatal dopamine 
function.20–24 The AUC for both glutamate and dopa-
mine measures indicated low discriminative accuracy. 
This indicates that these measures alone are unlikely to 
be sufficiently sensitive to identify chronic patients with 
antipsychotic nonresponsive from responsive illness in 
routine clinical practice.
The higher mean ACC Glucorr in NR is broadly 
consistent with cross-sectional14,26–28 and prospective 
studies29,30 associating higher levels of ACC glutamatergic 
Table 1. Clinical and Demographic Characteristics of the 1H-MRS Sample 
Antipsychotic Responder Antipsychotic Nonresponder P
Sample size 48 44  
Age (years) 29.9 ± 9.8 28.9 ± 7.5 .64
Sex male/female 41/7 36/8 .64
Ethnicity .96
 White 27 24
 Black 13 14
 Asian 4 3
 Other 4 3
Subtype .19
 Psychosis unspecified 15 7
 Schizophrenia 33 35
 Delusional disorder 0 1
 Schizoaffective disorder 0 1
Current antipsychotic .60
 Aripiprazole 11 8
 Olanzapine 15 7
 Risperidone 9 5
 Amisulpride 2 4
 Quetiapine 3 9
 Paliperidone 1 4
 Zuclopenthixol 2 1
 Flupentixol 1 1
 Haloperidol 1 0
 Combination 3 5
CPZE mg/day 426.5 ± 241.5 515.9 ± 379.6 .18
Other CNS medications
 None 40 34  
 Antidepressants 5 9 .15
 Benzodiazepines 4 6 .73
Age onset 24.6 ± 6.8 23.8 ± 6.4 .56
Duration of illness 5.1 ± 7.9 5.1 ± 5.1 .99
Tobacco daily/less than daily/not at all 21/4/23 17/3/24 .59
Cannabis ever Y/N 34/14 37/7 .25
Cannabis current Y/N 7/41 5/39 .76
Prior substance use disorder Y/N 1/47 0/44  
PANSS positive 12.0 ± 3.1 22.5 ± 3.5  
PANSS negative 13.5 ± 3.3 20.9 ± 4.8  
PANSS general 27.2 ± 4.3 43.3 ± 5.3  
PANSS total 52.7 ± 6.7 86.7 ± 8.8  
Note: Data are expressed as mean ± standard deviation unless otherwise specified. 1H-MRS, 1H-magnetic resonance spectroscopy; CNS, 
central nervous system; CPZE, chlorpromazine equivalent dose; PANSS, Positive and Negative Syndrome Scale. Current cannabis use 
was defined as use within the last 7 days. P values relate to independent samples t-tests, Chi square, or Fisher’s exact test as appropriate. 
There were no significant group differences in clinical or demographic characteristics other than in PANSS scores. 
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Table 2. Clinical and Demographic Characteristics of the 18F-DOPA PET Sample
Antipsychotic Responder Antipsychotic Nonresponder P
Sample size 25 29  
Age (years) 29.8 ± 9.6 30.0 ± 8.3 .86
Sex male/female 21/4 24/5 1.00
Ethnicity .77
 White 10 11
 Black 9 13
 Asian 3 3
 Other 3 2
Subtype .23
 Psychosis unspecified 8 6
 Schizophrenia 17 21
 Delusional disorder 0 1
 Schizoaffective disorder 0 1
Current antipsychotic 7 6 .53
 Aripiprazole 7 4
 Olanzapine Risperidone 5 2
 Amisulpride 2 3
 Quetiapine 1 4
 Paliperidone 0 4
 Clopixol 1 1
 Flupenthixol 1 1
 Haloperidol 1 0
 Combination 0 4
CPZE (mg/day) 404.8 ± 224.6 557.8 ± 420.9 .11
Other CNS medications  
 None 21 23
 Antidepressants 4 5 1.00
 Benzodiazepines 1 3 .62
Age onset 23.4 ± 5.5 24.1 ± 6.9 .72
Duration of illness 5.9 ± 9.1 5.9 ± 5.7 .98
Tobacco daily/less than daily/not at all 10/2/13 10/1/18 .57
Cannabis ever Y/N 17/8 23/6 .37
Cannabis current Y/N 3/22 3/26 1.00
PANSS positive 12.8 ± 3.2 22.0 ± 3.7  
PANSS negative 13.3 ± 3.1 22.3 ± 4.4  
PANSS general 27.0 ± 2.9 42.6 ± 5.1  
PANSS total 53.1 ± 5.5 86.9 ± 9.5  
18F-DOPA dose MBq 156.06 ± 15.93 155.01 ± 14.89 .81
Note: Data are expressed as mean ± standard deviation unless otherwise specified. 18F-DOPA PET, 3,4-dihydroxy-6-[18F]fluoro-l-
phenylalanine positron emission tomography; CNS, central nervous system; CPZE, chlorpromazine equivalent dose; PANSS, Positive 
and Negative Syndrome Scale. Current cannabis use was defined as use within the last 7 days. P values relate to independent samples 
t-tests, Chi square, or Fisher’s exact test as appropriate. There were no significant group differences in clinical or demographic character-
istics other than in PANSS scores.
metabolites with a poor antipsychotic response. However, 
these studies differ in the glutamate measurement (gluta-
mate or Glx) or Glu ratios (to creatine), sometimes cor-
rected for voxel tissue composition. In addition, 2 studies 
did not detect differences in ACC glutamate metabolites 
between a TRS and antipsychotic R group,28,33 and 1 
found ACC Glx, but not glutamate, was elevated in pa-
tients with ultra-resistant schizophrenia (URS) compared 
with healthy volunteers, but not in TRS or URS com-
pared with antipsychotic responders.27 Together with the 
current findings, the overall literature not only may indi-
cate an association between elevated ACC glutamatergic 
metabolites and antipsychotic nonresponse but also sug-
gests that effect sizes may be small and influenced by 
methodological factors and sample characteristics. In 
terms of biological mechanism, one explanation is that 
patients who are less likely to respond to treatment ex-
hibit greater elevations in frontal glutamate metabolites, 
potentially linked to a greater degree of  N-methyl-D-
aspartate (NMDA) receptor or  gamma-aminobutyric-
acid (GABA)ergic dysfunction resulting from genetic or 
developmental mechanisms. In addition, antipsychotic 
medication could have less impact on frontal glutamatergic 
dysfunction in those who respond poorly to treatment. 
In the striatum, the lack of group difference in Glucorr is 
consistent with 2 recent cross-sectional studies examining 
TRS to first-line antipsychotic responders or healthy vo-
lunteers.27,28 This could indicate that elevations in striatal 
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glutamate at illness onset31,32 are reduced during antipsy-
chotic treatment34 irrespective of the response category. 
Alternatively, as we also observed no group difference in 
striatal 18F-DOPA Ki
cer, these findings may indicate that 
the participants selected for our samples did not mark-
edly differ in the overall striatal pathophysiology.
In the 54 patients with dopamine measures evaluated 
across 2 sites, there was no group difference in striatal 
18F-DOPA Ki
cer, indicating similar levels of presynaptic 
dopamine synthesis and storage capacity. This finding 
differs from previous smaller studies that have associated 
increased striatal dopamine function with a good anti-
psychotic response.20–24 Using the same 18F-DOPA PET 
method, we reported lower striatal Ki
cer in 12 patients with 
TRS compared with 12 antipsychotic responders.20 In 
another study comparing a TRS group currently taking 
clozapine with antipsychotic-responsive patients, the re-
sistant group again had lower Ki
cer than the responders.21 
In first-episode psychosis, striatal Ki
cer was positively re-
lated to subsequent antipsychotic response.24 Lower 
Table 3. Glutamate and Dopamine Measures in the Antipsychotic Responder and Antipsychotic Nonresponder Groups
Antipsychotic Responder Antipsychotic Nonresponder ES, or GLM, Group GLM: Group, Age, and Sex 
1H-MRS glutamate (Glucorr)  
 Anterior cingulate cortex  
  KCL 19.39 ± 3.56 (16) 20.29 ± 2.63 (18) d = 0.29  
  UoM 13.74 ± 1.75 (17) 14.28 ± 1.59 (15) d = 0.74  
  UoE 12.57 ± 1.18 (7) 13.33 ± 0.90 (5) d = 0.72  
  CU 11.65 ± 1.68 (5) 11.57 ± 2.22 (3) d = 0.04  
  Overall −0.15 ± 1.05 (45) 0.17 ± 0.88 (41) F1,84 = 2.37; P = .13; η 
2 = 0.03 F1,81 = 4.99; P = .03; η 
2 = 0.06
 Right striatum
  KCL 10.78 ± 1.47 (16) 11.07 ± 1.62 (18) d = 0.19  
  UoM 8.35 ± 1.12 (17) 7.89 ± 1.01 (15) d = 0.43  
  UoE 8.67 ± 1.13 (5) 7.41 ± 1.21 (4) d =1.08  
  CU 9.00 ± 3.15 (4) 8.58 ± 1.43 (4) d = 0.17  
  Overall 0.10 ± 1.00 (42) −0.11 ± 0.96 (41) F1,81 = 0.96; P = .33; η 
2 = 0.12  
1H-MRS Glx (Glxcorr)
 Anterior cingulate cortex
  KCL 25.86 ± 5.28 (16) 26.85 ± 4.28 (18) d = 0.21  
  UoM 19.67 ± 2.56 (17) 20.17 ± 1.87 (15) d = 0.22  
  UoE 18.59 ± 1.61 (7) 19.62 ± 1.87 (5) d = 0.59  
  CU 14.82 ± 2.15 (5) 15.56 ± 2.14 (3) d = 0.34  
  Overall −0.13 ± 1.06 (45) 0.15 ± 0.88 (41) F1,84 = 1.77; P = .19; η 
2 = 0.02 F1,81 = 3.92; P = .05; η 
2 = 0.05
 Right striatum
  KCL 15.08 ± 2.65 (16) 14.27 ± 3.15 (18) d = 0.29  
  UoM 13.34 ± 1.81 (17) 12.89 ± 2.33 (15) d = 0.22  
  UoE 16.69 ± 5.84 (5) 12.70 ± 3.20 (4) d = 0.85  
  CU 11.75 ± 3.53 (4) 14.10 ± 3.41 (3) d = 0.68  
  Overall 0.13 ± 0.91 (42) −0.13 ± 1.04 (40) F1,81 = 1.39; P = .24; η 
2 = 0.01  
18F-DOPA PET Ki
cer  
 Whole striatum
  KCL 0.0125 ± 0.0095 (11) 0.0128 ± 0.0010 (16) d = 0.04  
  UoM 0.0139 ± 0.0013 (14) 0.0143 ± 0.0010 (13) d = 0.34  
  Overall −0.18 ± 1.05 (25) 0.12 ± 0.93 (29) F1,52 = 1.24; P = .27; η 
2 = 0.02  
 Sensorimotor striatum
  KCL 0.0126 ± 0.0011 (11) 0.0149 ± 0.0010 (16) d = 2.19  
  UoM 0.0149 ± 0.0016 (14) 0.0156 ± 0.0010 (13) d = 0.52  
  Overall −0.25 ± 0.96 (25) 0.16 ± 0.95 (29) F1,52 = 2.54; P = .12; η 
2 = 0.05  
 Associative striatum
  KCL 0.0126 ± 0.0010 (11) 0.0128 ± 0.0010 (16) d = 0.2  
  UoM 0.0136 ± 0.0014 (14) 0.0138 ± 0.0010 (13) d =0.16  
  Overall −0.13 ± 1.07 (25) 0.09 ± 0.95 (29) F1,52 = 0.62; P = .44; η 
2 = 0.01  
 Limbic striatum
  KCL 0.0122 ± 0.0010 (11) 0.0128 ± 0.0010 (16) d = 0.6  
  UoM 0.0136 ± 0.0012 (14) 0.0139 ± 0.0010 (13) d = 0.3  
  Overall −0.14 ± 1.05 (25) 0.12 ± 0.99 (29) F1,52 = 0.86; P = .36; η 
2 = 0.02  
Note: Data are presented by site and as overall Z-score. Data are expressed as mean ± standard deviation (number of observations). ES, 
effect size; GLM, general linear model; 1H-MRS, 1H-magnetic resonance spectroscopy; 18F-DOPA PET, 3,4-dihydroxy-6-[18F]fluoro-l-
phenylalanine positron emission tomography; KCL, King’s College London; UoM, University of Manchester; UoE, University of Edin-
burgh; CU, Cardiff  University.
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Fig. 1. Glutamate and dopamine measures in the antipsychotic 
responder and antipsychotic nonresponder groups. Glutamate 
is expressed as the corrected 1H-MRS glutamate concentration 
(Glucorr) in the anterior cingulate cortex (ACC) and right striatum. 
Dopamine synthesis was measured as 18F-DOPA Ki
cer min−1 
across the whole striatum. Values are presented as Z-scores. Data 
are shown in antipsychotic responder (R) and antipsychotic 
nonresponder (NR) groups. 
Fig. 2. Receiver operating characteristic (ROC) curve of the 
ability for glutamate (Glucorr) in the anterior cingulate cortex 
(ACC) to discriminate the antipsychotic responder (R) and 
antipsychotic nonresponder (NR) groups. The area under curve 
(AUC) is 0.59. The straight line represents chance performance.
availability of D2 receptors for radiotracer binding, 
which may reflect increased D2 occupancy by dopamine, 
was also associated with subsequent response to 6 weeks 
of treatment with amisulpride.23 A  dopamine depletion 
study also indicated that higher levels of synaptic dopa-
mine are predictive of a good antipsychotic response.22
Within cortico-striatal networks, counterbalancing 
pathways and feedback loops regulate neurotransmitter 
balance.62 For example, glutamate release can both 
increase and decrease dopamine levels,63 dopamine re-
ceptor activation modulates glutamate release,64 and 
dopamine neurons may co-release glutamate.65 In NR 
only, ACC Glucorr was positively correlated to striatal 
18F-DOPA Ki
cer. In contrast, striatal Glucorr and striatal 
Ki
cer were negatively correlated across the whole sample. 
We previously found that ACC glutamate and striatal 
Ki
cer were negatively correlated in patients with early 
psychosis and no significant relationship between these 
variables in healthy controls.66 Correlations between stri-
atal glutamate and striatal Ki
cer have not previously been 
investigated in patients but are positively correlated in 
healthy volunteers.67 Together these findings could sug-
gest that glutamate-dopamine relationships may change 
with illness onset, progression, or antipsychotic response. 
One potential mechanism may involve alterations in 
the balance between the opposing influences of direct 
and indirect glutamatergic projections from the cortex 
to mesostriatal dopamine neurons. This interpretation 
could be further examined in animal models and in lon-
gitudinal patient studies over the course of antipsychotic 
treatment.
Relative to previous research, a strength of the current 
study is the large sample size, which reduces the risk of 
false-positive findings. There are also design differences 
compared with previous studies that may contribute to 
the lack of group difference in dopamine measures and 
the marginal group difference in ACC glutamate meas-
ures. The criteria used to define the antipsychotic NR 
and R groups may have led to less clinical separation of 
these groups than in our previous 18F-DOPA PET20 and 
1H-MRS14 studies. In the current study, the R group cri-
teria allowed a higher level of symptom severity, while the 
NR group was less symptomatic and met fewer of the cri-
teria for establishing treatment resistance.68 In addition, 
although the 2 groups were relatively well-matched for 
medication, we did not confirm adherence by measuring 
blood plasma antipsychotic levels. It is thus possible that 
the NR group may have included some participants whose 
symptoms were high because of partial nonadherence, 
rather than because they were “true” nonresponders.69
Further strengths of our study include the establish-
ment of collaborative multicenter 1H-MRS and PET 
imaging in the UK, which allowed us to achieve a large 
sample size for both 1H-MRS and 18F-DOPA PET im-
aging. With a view toward developing predictive bio-
markers for stratified clinical trials, we formally assessed 
the accuracy of these measures for classifying anti-
psychotic response and nonresponse. In our previous 
multicenter 1H-MRS study in first-episode psychosis, our 
a priori outcome variable was glutamate in ratio to cre-
atine.29 In the current multicenter study, we were able to 
correct glutamate estimates for voxel tissue composition 
(Glucorr, our primary outcome variable) by applying the 
same software (Gannet) to extract voxel tissue fractions 
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in data acquired across different MRI systems. This has 
the advantage that potential influences of voxel creatine 
content (otherwise often used as an internal standard) are 
avoided (see supplementary Discussion).
Our study also has several limitations. It is not possible 
to establish the proportion of the NR group that would 
meet Treatment Response and Resistance In Psychosis 
(TRRIP) consensus requirements for “TRS” 68 as we did 
not include a prospective trial of antipsychotic medica-
tion or collect objective evidence of adherence. As we 
only collected clinical data at a single time-point, we did 
not establish the stability of R/NR status. These factors 
could have led to a less clinical separation between the R 
and NR groups and reduced our ability to observe differ-
ences in glutamate or dopamine measures. While the R 
and NR groups did not differ in duration of illness or cur-
rent antipsychotic dose, the inclusion of patients who had 
been taking antipsychotic medication for some time may 
have influenced both 18F-DOPA Ki
cer70 and 1H-MRS glu-
tamate71 values. The absence of a healthy control group 
means that we are unable to interpret 1H-MRS glutamate 
and 18F-DOPA Ki
cer values in comparison to what may 
be expected in psychiatrically healthy individuals. Neither 
the 1H-MRS glutamate nor 18F-DOPA PET dopamine 
imaging measures specifically index neurotransmission. 
1H-MRS estimates the total amount of intracellular glu-
tamate in the voxel, including neurons as well as other cell 
types. 18F-DOPA is used to index presynaptic dopamine 
synthesis and storage capacity rather than dopamine re-
lease. Previous studies of glutamate in relation to anti-
psychotic response/nonresponse at a field strength of 3 
tesla have detected differences in glutamate or Glx.14,26–30 
Although glutamate values obtained with short TE 
PRESS at 3 tesla are routinely reported and published, 
glutamate can be difficult to reliably quantify without 
specialized sequences. Despite the fitting methods, the 
glutamate signal is likely to include some contamination 
from glutamine and macromolecules and this may vary 
across the site. As for other imaging modalities, there was 
between-scanner variation in both 1H-MRS and PET 
data, which will have reduced the sensitivity of our study. 
Although we did not detect significant site by group inter-
actions, we cannot exclude the possibility that scanner 
variation impacted our results. Between-scanner variation 
is discussed further in the supplementary Discussion.
The results highlight the importance of considering 
age and sex effects in future studies of glutamate in schiz-
ophrenia. A lower level of ACC Glucorr in older patients 
with schizophrenia is consistent with other reports.59,72 
There is some evidence that age-related decline in ACC 
glutamate58 is greater in schizophrenia than in healthy 
aging,60,72 although other studies have reported similar 
rates of ACC glutamate decrease in patients and healthy 
volunteers.59,73 Our finding of higher ACC Glucorr levels in 
male compared with female participants is less clear due 
to the relatively small number of female participants.
In conclusion, our findings support previous research 
linking increases in ACC glutamate to a poor antipsy-
chotic response. However, the poor group discrimination 
suggests that glutamate 1H-MRS or 18F-DOPA measures 
alone cannot distinguish between antipsychotic respon-
sive and nonresponsive groups after a mean of 5–6 years 
of illness. Multicenter, cross-platform 1H-MRS and PET 
studies are rare, and in future studies, sensitivity may be 
improved through greater harmonization. It is also pos-
sible that glutamatergic and dopaminergic markers may 
have more predictive power earlier in the course of the 
disorder before the potentially confounding effects of 
treatment and illness duration have taken effect. They 
may also have increased predictive power in combination 
with other factors that may associate with antipsychotic 
response, such as clinical and demographic measures,11–13 
brain network connectivity,74 genetic factors,75,76 and 
blood measures.77 We plan to address these issues in fu-
ture studies.
Supplementary Material
Supplementary material is available at Schizophrenia 
Bulletin.
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